MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. on November 15, 2023, covering events occurring between November 10 and November 15, 2023. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Chicago, Illinois. The filing addresses significant corporate governance changes, the termination of a material financing agreement, and a potential delisting notice from NYSE American.
Key Financial Metrics and Liquidity
The filing provides limited financial data, primarily related to a terminated equity offering and historical equity levels:
- Stockholders' Equity: Approximately $2.7 million as of September 30, 2023.
- ATM Program Proceeds: Under a terminated Sales Agreement with ThinkEquity LLC, the Company sold 758,388 shares for gross proceeds of $1,667,084.40 through November 15, 2023.
- Severance Obligations: The Company incurred immediate severance liabilities of $330,000 for the former CFO and $418,000 for the former CMO, plus 30 days of base salary for each.
- Profitability: The Company reported losses from continuing operations and/or net losses in each of the fiscal years ended December 31, 2020, 2021, and 2022.
The filing text does not provide current revenue, operating cash flow, or total debt figures.
Material Changes and Corporate Actions
Significant operational and structural changes occurred during the reporting period:
- Termination of Sales Agreement: The Company suspended sales and provided notice to terminate its "at-the-market" equity offering program with ThinkEquity LLC, effective 10 days after November 15, 2023.
- Executive Departures: Joseph McGuire (CFO) and Dr. Mihail Obrocea (CMO) were terminated effective November 10, 2023, as part of an effort to streamline operations. The departures were not due to disagreements with company policies.
- New Appointment: Jeffrey Himmelreich was appointed Head of Finance and principal financial and accounting officer on November 10, 2023. His annual base salary is $210,000 with a potential 20% performance bonus.
Outlook, Risks, and Contingencies
The Company faces a material risk regarding its continued listing on NYSE American:
- Delisting Notice: On November 14, 2023, NYSE American orally advised the Company that it does not believe MAIA is in compliance with continued listing standards regarding stockholders' equity.
- Compliance Requirement: The standard requires listed companies with losses in three of the four most recent fiscal years to maintain stockholders' equity of at least $4 million. MAIA's equity of $2.7 million falls below this threshold.
- Current Status: As of the filing date, the Company has not received a formal written notice from the exchange regarding this matter.
Key Facts for Investor Verification
- Verify the Company's plan to address the NYSE American stockholders' equity deficiency ($2.7 million vs. $4 million requirement) to avoid delisting.
- Confirm the impact of the terminated ATM program on the Company's future capital raising capabilities and liquidity.
- Monitor the transition of financial reporting responsibilities under the new Head of Finance, Jeffrey Himmelreich.
- Review the Company's cash burn rate and runway given the history of net losses and the cessation of the ATM offering.